BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35624513)

  • 1. Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study.
    Jovanovic DM; Šterclová M; Mogulkoc N; Lewandowska K; Müller V; Hájková M; Studnicka M; Tekavec-Trkanjec J; Littnerová S; Vašáková M;
    Respir Res; 2022 May; 23(1):135. PubMed ID: 35624513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis.
    Tran T; Šterclová M; Mogulkoc N; Lewandowska K; Müller V; Hájková M; Kramer MR; Jovanović D; Tekavec-Trkanjec J; Studnicka M; Stoeva N; Hejduk K; Dušek L; Suissa S; Vašáková M;
    Respir Res; 2020 Jan; 21(1):11. PubMed ID: 31915023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue.
    Caminati A; Lonati C; Cassandro R; Elia D; Pelosi G; Torre O; Zompatori M; Uslenghi E; Harari S
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
    Doubková M; Švancara J; Svoboda M; Šterclová M; Bartoš V; Plačková M; Lacina L; Žurková M; Binková I; Bittenglová R; Lošťáková V; Merta Z; Šišková L; Tyl R; Lisá P; Šuldová H; Petřík F; Pšikalová J; Řihák V; Snížek T; Reiterer P; Homolka J; Musilová P; Lněnička J; Palúch P; Hrdina R; Králová R; Hortvíková H; Strenková J; Vašáková M
    Clin Respir J; 2018 Apr; 12(4):1526-1535. PubMed ID: 28862397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory comorbidities and risk of mortality in hospitalized patients with idiopathic pulmonary fibrosis.
    Oda K; Yatera K; Fujino Y; Kido T; Hanaka T; Sennari K; Fushimi K; Matsuda S; Mukae H
    Respir Investig; 2018 Jan; 56(1):64-71. PubMed ID: 29325684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.
    Gao J; Kalafatis D; Carlson L; Pesonen IHA; Li CX; Wheelock Å; Magnusson JM; Sköld CM
    Respir Res; 2021 Feb; 22(1):40. PubMed ID: 33546682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis.
    Aggarwal R; McBurney C; Schneider F; Yousem SA; Gibson KF; Lindell K; Fuhrman CR; Oddis CV
    Rheumatology (Oxford); 2017 Mar; 56(3):384-389. PubMed ID: 28082622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis.
    Kreuter M; Ehlers-Tenenbaum S; Palmowski K; Bruhwyler J; Oltmanns U; Muley T; Heussel CP; Warth A; Kolb M; Herth FJ
    PLoS One; 2016; 11(3):e0151425. PubMed ID: 27023440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clusters of comorbidities in idiopathic pulmonary fibrosis.
    Prior TS; Hoyer N; Hilberg O; Shaker SB; Davidsen JR; Rasmussen F; Bendstrup E
    Respir Med; 2021; 185():106490. PubMed ID: 34130097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
    Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
    Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How does comorbidity influence survival in idiopathic pulmonary fibrosis?
    Hyldgaard C; Hilberg O; Bendstrup E
    Respir Med; 2014 Apr; 108(4):647-53. PubMed ID: 24529739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis.
    Fisher JH; Kolb M; Algamdi M; Morisset J; Johannson KA; Shapera S; Wilcox P; To T; Sadatsafavi M; Manganas H; Khalil N; Hambly N; Halayko AJ; Gershon AS; Fell CD; Cox G; Ryerson CJ
    BMC Pulm Med; 2019 Nov; 19(1):223. PubMed ID: 31771541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.
    Wong AW; Lee TY; Johannson KA; Assayag D; Morisset J; Fell CD; Fisher JH; Shapera S; Gershon AS; Cox G; Halayko AJ; Hambly N; Manganas H; Sadatsafavi M; Wilcox PG; To T; Marcoux V; Khalil N; Kolb M; Ryerson CJ
    Respir Res; 2020 Dec; 21(1):322. PubMed ID: 33287805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.
    Ryerson CJ; Hartman T; Elicker BM; Ley B; Lee JS; Abbritti M; Jones KD; King TE; Ryu J; Collard HR
    Chest; 2013 Jul; 144(1):234-240. PubMed ID: 23370641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry.
    Swaminathan AC; Hellkamp AS; Neely ML; Bender S; Paoletti L; White ES; Palmer SM; Whelan TPM; Dilling DF;
    Ann Am Thorac Soc; 2022 Jun; 19(6):981-990. PubMed ID: 35073248
    [No Abstract]   [Full Text] [Related]  

  • 16. Idiopathic Pulmonary Fibrosis Among Young Patients: Challenges in Diagnosis and Management.
    Leuschner G; Reiter F; Stocker F; Crispin A; Kneidinger N; Veit T; Klenner F; Ceelen F; Zimmermann G; Leuchte H; Reu S; Dinkel J; Behr J; Neurohr C
    Lung; 2018 Aug; 196(4):401-408. PubMed ID: 29761229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underlying and immediate causes of death in patients with idiopathic pulmonary fibrosis.
    Kärkkäinen M; Nurmi H; Kettunen HP; Selander T; Purokivi M; Kaarteenaho R
    BMC Pulm Med; 2018 May; 18(1):69. PubMed ID: 29751748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins: cause of fibrosis or the opposite? Effect of cardiovascular drugs in idiopathic pulmonary fibrosis.
    M Lambert E; A Wuyts W; Yserbyt J; De Sadeleer LJ
    Respir Med; 2021 Jan; 176():106259. PubMed ID: 33276250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden.
    Kalafatis D; Gao J; Pesonen I; Carlson L; Sköld CM; Ferrara G
    BMC Pulm Med; 2019 Nov; 19(1):222. PubMed ID: 31771560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities.
    Caminati A; Madotto F; Conti S; Cesana G; Mantovani L; Harari S
    Intern Emerg Med; 2021 Oct; 16(7):1793-1802. PubMed ID: 33586036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.